Phaseline

Companies › McNeil

McNeil: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Other; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Nicotine
Neuronal acetylcholine receptor; alpha4/beta2 agonist
CHRNB2, CHRNA4Phase 2Smoking CessationOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07893158NicotinePhase 2Smoking CessationOtherOct 2027

Targets

CHRNB2 (1) CHRNA4 (1)

Companies with the same targets

JT International

Companies built like this

Healx Skingenix Sensory Cloud Shanghai Huilun Pharmaceutical Dendrogenix

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.